Government, Officials Defend AstraZeneca's COVID-19 Shot: CNBC
Government, Officials Defend AstraZeneca's COVID-19 Shot: CNBC
政府，官员为阿斯利康的新冠肺炎注射辩护：CNBC
- The British government and health experts in the country have come forward to defend the COVID-19 vaccine developed by AstraZeneca plc’s (NASDAQ: AZN) and Oxford after a possible link to blood clots have raised concerns, reports CNBC.
- One Twitter user commented Thursday that officials appear to have gone into “damage limitation” mode.
- Yesterday, European Medicines Agency concluded that unusual blood clots should be listed as a “very rare side effect” of the AZN COVID-19 shot. The EMA has not placed any age restrictions on recipients, however.
- The U.K.’s health and vaccine regulators issued a change of guidance over who should receive the shot, and now they recommend that anyone under 30 years of age should go for an alternative vaccine amid the concerns.
- Following a safety review of the AstraZeneca vaccine, both the U.K. and European medicines regulators stressed that the shot’s benefits still outweighed the risks.
- Meanwhile, U.K. Prime Minister Boris Johnson, who has received a first shot of the vaccine himself, said that “the best thing people should do is look at what the MHRA said. “Their advice to people is to keep going out there, get your jab, get your second jab,” he added.
- “It does sound like a sensible decision based on the evidence we have so far of a probable causal link between the AZ vaccine and these very rare thrombotic side effects that have been noted,” Andrew Freedman, reader in infectious diseases at Cardiff University School of Medicine, told CNBC. However, he noted that vaccine hesitancy was now “clearly a concern.”
- EMA’s Executive Director Emer Cooke noted that researchers were still trying to determine what has been causing a small number of severe but rare clots, including cerebral venous sinus thrombosis.
- To date, four European countries have stopped using the AstraZeneca vaccine altogether, including Denmark and the Netherlands. In contrast, others, including Germany, France, and Spain, have put age restrictions on the shot.
- Price Action: AZN shares are trading 2.3% higher at $49.54 on the last check Thursday.
- 英国政府和该国的卫生专家挺身而出，为英国政府研发的新冠肺炎疫苗辩护。阿斯利康(AstraZeneca Plc)据CNBC报道，纳斯达克(Nasdaq：AZN)和牛津大学(Oxford)在可能与血液凝块有关后，已经提出了担忧。
- 一位推特用户周四评论说，官员们似乎已经进入了“损害限制”模式。
- 昨天，欧洲药品管理局得出结论，不寻常的血栓应该被列为注射氮磷新冠肺炎的“非常罕见的副作用”。然而，EMA没有对接受者施加任何年龄限制。
- 英国卫生和疫苗监管机构就谁应该接种疫苗发布了新的指导意见，现在他们建议30岁以下的人都应该选择替代疫苗，因为人们对此感到担忧。在这种情况下，英国的卫生和疫苗监管机构发布了一项新的指导意见，建议30岁以下的人接种替代疫苗。
- 在对阿斯利康(AstraZeneca)疫苗进行安全性审查后，英国和欧洲药品监管机构都强调，注射的好处仍然大于风险。
- 与此同时，英国首相鲍里斯·约翰逊(Boris Johnson)表示，“人们应该做的最好的事情就是看看MHRA说了什么。”约翰逊本人也已经接种了第一针疫苗。他补充说：“他们给人们的建议是继续走出去，打你的针，打你的第二针。”
- 卡迪夫大学医学院传染病读者安德鲁·弗里德曼告诉CNBC：“根据我们迄今掌握的证据，AZ疫苗和这些已经注意到的非常罕见的血栓副作用之间可能存在因果联系，这听起来确实是一个明智的决定。”然而，他指出，疫苗的犹豫不决现在“显然是一个令人担忧的问题”。
- EMA的执行主任Emer Cooke指出，研究人员仍在努力确定是什么导致了少量严重但罕见的血栓，包括脑静脉窦血栓形成。
- 到目前为止，包括丹麦和荷兰在内的四个欧洲国家已经完全停止使用阿斯利康疫苗。相比之下，包括德国、法国和西班牙在内的其他国家则对拍摄施加了年龄限制。
- 价格行动：在周四的最后一次检查中，AZN股价上涨2.3%，至49.54美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。